Get the Stockscreener App
0.2725
23.58%
-0.0841
After Hours:
.27
-0.0025
-0.92%
Transcode Therapeutics Inc Stock (RNAZ) Forecast
The Transcode Therapeutics Inc (RNAZ) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $13.28, representing a +4,774% increase from the current price of $0.2725. The highest analyst price target is $13.08, and the lowest is $13.48.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RNAZ Price Target
Average 15.73
(+5,673% Upside)
Is Transcode Therapeutics Inc (RNAZ) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 25.95 | Buy |
| STOCH(9,6) | 22.72 | Neutral |
| STOCHRSI(14) | 6.7114 | Buy |
| MACD(12,26) | -0.5722 | Buy |
| ADX(14) | 13.56 | Neutral |
| William %R | -86.44 | Buy |
| CCI(14) | -60.24 | Neutral |
Buy: 4
Sell: 0
Neutral: 3
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.3912
Sell
|
0.4052
Sell
|
| MA20 |
0.5022
Sell
|
0.7072
Sell
|
| MA50 |
3.1933
Sell
|
2.4047
Sell
|
| MA100 |
4.8125
Sell
|
5.634
Sell
|
| MA200 |
10.09
Sell
|
16.17
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, RNAZ could be considered a Strong Sell, with 17 technical analysis indicators signaling 4 Buy signals, 10 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on RNAZ, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 25.95 indicates that RNAZ is oversold. This indicates that RNAZ price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 22.72 indicates that RNAZ is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 6.7114 indicates that RNAZ is oversold. This suggests that RNAZ price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 13.56 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -60.24 indicates that RNAZ is still oversold but not to an extreme extent.
Long-term RNAZ price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Transcode Therapeutics Inc financial reports and earnings history, Transcode Therapeutics Inc (RNAZ) stock could reach $23.32 by 2030, $279.62 by 2040 and $381.74 by 2050. See the projected annual prices until 2050 of the Transcode Therapeutics Inc stock below:
- Transcode Therapeutics Inc (RNAZ) is expected to reach an average price of $111.96 in 2035, with a high prediction of $114.24 and a low estimate of $114.16. This indicates an $40,986% rise from the last recorded price of $0.2725.
- Transcode Therapeutics Inc (RNAZ) stock is projected to chart a bullish course in 2040, with an average price target of $283.22, representing an $103.83K% surge from its current level. The forecast ranges from a conservative $4.2363 to a sky-high $279.62.
- Our analysts predict Transcode Therapeutics Inc (RNAZ) to jump 58,083% by 2045, soaring from $158.73 to an average price of $158.55, potentially reaching $161.33. While $158.73 is the low estimate, the potential upside is significant.
- Transcode Therapeutics Inc (RNAZ) stock is expected to climb by 2050, reaching an average of $376.99, a $138.25K% jump from its current level. However, a wide range of estimates exists, with high and low targets of $381.74 and $377.49, respectively, highlighting the market's uncertainty.
Transcode Therapeutics Inc Stock (RNAZ) Year by Year Forecast
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2025
Transcode Therapeutics Inc Stock (RNAZ) is expected to reach an average price of $10.88 in 2025, with a high prediction of $20.74 and a low estimate of $1.0216. This indicates an +3,892% rise from the last recorded price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $10.14 | $13.48 | $13.08 | +3,622% |
| June, 2025 | $7.8709 | $11.17 | $9.7979 | +2,788% |
| July, 2025 | $11.06 | $10.73 | $9.6591 | +3,958% |
| August, 2025 | $11.49 | $13.69 | $9.8447 | +4,116% |
| September, 2025 | $16.86 | $11.46 | $8.7069 | +6,089% |
| October, 2025 | $20.63 | $18.75 | $19.71 | +7,472% |
| November, 2025 | $20.44 | $20.64 | $20.74 | +7,401% |
| December, 2025 | $13.66 | $16.41 | $19.30 | +4,912% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2026
The predicted value for Transcode Therapeutics Inc (RNAZ) in 2026 is set at an average of $12.93. Estimates vary from a peak of $16.54 to a trough of $9.3138, indicating an +4,644% surge from the present price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $16.26 | $12.37 | $13.56 | +5,866% |
| February, 2026 | $15.39 | $15.64 | $15.15 | +5,547% |
| March, 2026 | $16.45 | $16.44 | $16.54 | +5,936% |
| April, 2026 | $15.10 | $15.49 | $14.71 | +5,442% |
| May, 2026 | $15.94 | $15.25 | $15.10 | +5,749% |
| June, 2026 | $16.20 | $16.05 | $16.31 | +5,844% |
| July, 2026 | $14.74 | $14.78 | $15.74 | +5,308% |
| August, 2026 | $14.05 | $14.13 | $14.31 | +5,055% |
| September, 2026 | $13.31 | $13.23 | $13.56 | +4,783% |
| October, 2026 | $12.17 | $12.21 | $12.77 | +4,367% |
| November, 2026 | $10.88 | $10.89 | $11.73 | +3,893% |
| December, 2026 | $9.3053 | $9.3138 | $10.41 | +3,315% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Transcode Therapeutics Inc (RNAZ) is $27.32, with a high forecast of $54.26 and a low forecast of $0.3753. This indicates an +9,924% increase from the last price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $7.99 | $7.9948 | $8.9419 | +2,832% |
| February, 2027 | $6.0255 | $6.0654 | $7.6475 | +2,111% |
| March, 2027 | $4.3861 | $4.4288 | $5.563 | +1,510% |
| April, 2027 | $3.0131 | $3.1301 | $3.9872 | +1,006% |
| May, 2027 | $1.7134 | $1.7347 | $2.6428 | +528.77% |
| June, 2027 | $56.14 | $0.3753 | $52.54 | +20,502% |
| July, 2027 | $56.81 | $53.29 | $54.26 | +20,747% |
| August, 2027 | $48.06 | $52.46 | $52.43 | +17,538% |
| September, 2027 | $47.84 | $50.18 | $47.38 | +17,456% |
| October, 2027 | $48.10 | $47.07 | $45.60 | +17,551% |
| November, 2027 | $47.56 | $48.42 | $44.85 | +17,354% |
| December, 2027 | $55.14 | $48.91 | $47.53 | +20,134% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2028
In 2028, Transcode Therapeutics Inc (RNAZ) is projected to reach an average price of $40.89, with a high projection of $51.37 and a low estimate of $30.41. This indicates an +14,905% rise from the last price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $51.50 | $49.68 | $49.05 | +18,799% |
| February, 2028 | $45.46 | $49.22 | $45.94 | +16,582% |
| March, 2028 | $30.24 | $31.64 | $41.98 | +10,996% |
| April, 2028 | $29.50 | $30.53 | $27.10 | +10,725% |
| May, 2028 | $43.87 | $30.41 | $42.67 | +16,000% |
| June, 2028 | $52.33 | $44.79 | $50.32 | +19,105% |
| July, 2028 | $48.80 | $49.20 | $51.37 | +17,807% |
| August, 2028 | $46.37 | $46.96 | $43.83 | +16,917% |
| September, 2028 | $46.43 | $46.52 | $45.09 | +16,940% |
| October, 2028 | $41.89 | $45.29 | $43.35 | +15,274% |
| November, 2028 | $51.27 | $43.93 | $49.19 | +18,715% |
| December, 2028 | $52.13 | $51.47 | $50.53 | +19,031% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2029
The 2029 price forecast for Transcode Therapeutics Inc Stock (RNAZ) is $37.31 on average, with a high prediction of $50.46 and a low estimate of $24.16. This represents an +13,592% increase from the previous price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $43.25 | $49.51 | $50.46 | +15,771% |
| February, 2029 | $38.67 | $42.27 | $42.54 | +14,091% |
| March, 2029 | $40.73 | $39.01 | $39.52 | +14,848% |
| April, 2029 | $40.51 | $40.23 | $40.43 | +14,767% |
| May, 2029 | $37.18 | $38.42 | $40.10 | +13,543% |
| June, 2029 | $36.29 | $36.53 | $36.21 | +13,217% |
| July, 2029 | $35.64 | $35.84 | $35.45 | +12,979% |
| August, 2029 | $33.89 | $33.94 | $35.42 | +12,335% |
| September, 2029 | $31.23 | $31.29 | $32.56 | +11,360% |
| October, 2029 | $28.55 | $28.55 | $30.48 | +10,379% |
| November, 2029 | $26.60 | $26.77 | $27.76 | +9,662% |
| December, 2029 | $24.15 | $24.16 | $25.38 | +8,763% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2030
Transcode Therapeutics Inc Stock (RNAZ) is expected to reach an average price of $56.01 in 2030, with a high forecast of $110.68 and a low forecast of $1.3405. This signifies an +20,455% surge from the last price of $0.2725.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $20.84 | $20.85 | $23.32 | +7,548% |
| February, 2030 | $18.16 | $18.16 | $20.15 | +6,563% |
| March, 2030 | $15.48 | $15.48 | $17.46 | +5,580% |
| April, 2030 | $12.20 | $12.20 | $14.76 | +4,375% |
| May, 2030 | $8.7579 | $8.7822 | $11.45 | +3,114% |
| June, 2030 | $6.0573 | $6.1136 | $8.0377 | +2,123% |
| July, 2030 | $2.75 | $2.8799 | $5.3498 | +909.19% |
| August, 2030 | $114.88 | $1.3405 | $110.68 | +42,059% |
| September, 2030 | $109.18 | $109.03 | $107.18 | +39,964% |
| October, 2030 | $105.64 | $103.87 | $107.15 | +38,667% |
| November, 2030 | $90.33 | $101.13 | $97.96 | +33,049% |
| December, 2030 | $96.82 | $98.70 | $96.55 | +35,431% |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):